What it sells
A financial intelligence platform for life sciences.
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D finance (FP&A), ClinOps and CXO at enterprise and mid-sized biopharma, MedTech and CROs
Trigger: what makes them buy now?
Clinical, operational and financial data live in disconnected CTMS, EDC, procurement, ERP and planning systems, slowing trial decisions.
Workflow: what inputs become what output?
Connect pulls data from existing systems with no rip-and-replace; AI workflows and an FP&A agent produce R&D spend analysis and explain the why behind numbers.
Distribution: how it reaches customers
Demo-led plus partner and referral programs.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-03-18 | Series A | $24M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.